• 1
    Brandes AA, Scelzi E, Salmistraro G, Ermani M, Carollo C, Berti F, Zampieri P, Baiocchi C, Fiorentino MV. Incidence of risk of thromborembolism during treatment high-grade gliomasL a prospective study. Eur J Cancer 1997; 33: 15926.
  • 2
    Cheruku R, Tapazoglou E, Ensley J, Kish JA, Cummings GD, Al-Sarraf M. The incidence and significance of thromboembolic complications in patients with high-grade gliomas. Cancer 1991; 68: 26214.
  • 3
    Marras LC, Geerts WH, Perry JR. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer 2000; 89: 6406.
  • 4
    Pan E, Tsai JS, Mitchell SB. Retrospective study of venous thromboembolic and intracerebral hemorrhagic events in glioblastoma patients. Anticancer Res 2009; 29: 430913.
  • 5
    Semrad TJ, O’Donnell R, Wun T, Chew H, Harvey D, Zhou H, White RH. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg 2007; 106: 6018.
  • 6
    Ruff RL, Posner JB. Incidence and treatment of peripheral venous thrombosis in patients with glioma. Ann Neurol 1983; 13: 3346.
  • 7
    Hamada K, Kuratsu J, Saitoh Y, Takeshima H, Nishi T, Ushio Y. Expression of tissue factor correlates with grade of malignancy in human glioma. Cancer 1996; 77: 187783.
  • 8
    Kayser-Gatchalian MC, Kayser K. Thrombosis and intracranial tumors. J Neurol 1975; 209: 21724.
  • 9
    Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol 2009; 27: 483947.
  • 10
    Rickles FR, Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res 2001; 102: 21524.
  • 11
    Sawaya R, Zuccarello M, Elkalliny M, Nishiyama H. Postoperative venous thromboembolism and brain tumors: Part I. Clinical profile. J Neurooncol 1992; 14: 11925.
  • 12
    Sawaya R, Ligon L. Thromboembolic complications associated with brain tumors. J Neurooncol 1994; 22: 17381.
  • 13
    Dentali F, Douketis J, Gianni M, Lim W, Crowther MA. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med 2007; 146: 27888.
  • 14
    Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guideline (8th Edition). Chest 2008; 133: 381S453S.
  • 15
    Choucair AK, Silver P, Levin VA. Risk of intracranial hemorrhage in glioma patients receiving anticoagulant therapy for venous thromboembolism. J Neurosurg 1987; 66: 3578.
  • 16
    Gallus AS. Prevention of post-operative deep leg vein thrombosis in patients with cancer. Thromb Haemost 1997; 78: 12632.
  • 17
    Kakkar AK, Williamson RC. Thromboprophylaxis in the cancer patient. Haemostasis 1998; 28(Suppl. 3): S615.
  • 18
    Rana P, Levine MN. Prevention of thrombosis in ambulatory patients with cancer. J Clin Oncol 2009; 27: 48858.
  • 19
    Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral Anticoagulants. Chest 2008; 133(Suppl. 6): 141S59S.
  • 20
    Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low molecular weight heparins compared with unfractionated heparin for treatment of acute deep vein thrombosis: a meta-analysis of randomized controlled trials. Ann Intern Med 1999; 130: 8009.
  • 21
    Agnelli G, Piovella F, Buoncristiani P, Severi P, Pini M, D’Angelo A, Beltrametti C, Damiana M, Andrioli GC, Pugliese R, Iorio A, Brambilla G. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective surgery. N Engl J Med 1998; 339: 805.
  • 22
    Nurmohamed MT, Van Riel AM, Henkens CM, Koopman MM, Que GT, D’Azemar P, Buller HR, Ten Cate JW, Hoek JA, Van Der Meer J, Van Der Heul C, Turpie AG, Haley S, Sicurella A, Gent M. Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. Thromb Haemost 1996; 75: 2338.
  • 23
    Perry SL, Bohlin C, Reardon DA, Desjardins A, Friedman AH, Friedman HS, Vredenburgh JJ. Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients. J Neurooncol 2009; 95: 12934.
  • 24
    Robins HI, O’Neill A, Gilbert M, Olsen M, Sapiente R, Berkey B, Mehta M. Effect of dalteparin and radiation on survival and thromboembolic events in glioblastoma multiforme: a phase II ECOG trial. Cancer Chemother Pharmacol 2008; 62: 22733.
  • 25
    Akl EA, Van Doormaal FF, Barba M, Kamath G, Kim SY, Kuipers S, Middeldorp S, Yosvico V, Dickinson HO, Schunemann HJ. Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation. Cochrane Database Syst Rev 2007; CD006652.
  • 26
    Kuderer NM, Ortel TL, Francis CW. Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J Clin Oncol 2009; 27: 490211.
  • 27
    Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 14653.
  • 28
    Ay C, Vormittag R, Dunkler D, Simanek R, Chiriac AL, Drach J, Quehenberger P, Wagner O, Zielinski C, Pabinger I. D-dimer and prothrombin fragment 1+2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2009; 27: 4124219.
  • 29
    Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111: 49027.